Status: Recruiting
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
This is a Phase I, prospective, dose-finding study to evaluate the safety, persistence, and clinical activity of GF-CART01 in subjects aged 18-70 with relapsed or refractory (R/R) B-cell hematological malignancies and failure of two-line or more standard chemotherapies or auto-hematopoietic stem cell transplantation (HSCT).This study is a traditional 3+3 dose-escalation design to observe dose-limiting toxicity (DLT), establish the maximum tolerated dose(MTD)/recommended phase 2 doses (RP2D), and preliminary efficacy of GF-CART01. RP2D may equal to or lower than MTD
Participants needed: 18
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: GenomeFrontier Therapeutics TW Co., Ltd.Updated: Jun 12, 2026Locations: 1
Eligibility criteria
Subjects must be of age ≥ 18 years and ≤ 70 years [+14]
Previously treated with any CAR T cell product or allogenic hematopoietic stem c... [+15]